Graphic Designer

AliveCor launches KardiaACCESS: A medicare-covered program built to improve blood pressure, diabetes, and heart health. Under the new CMS ACCESS Model, eligible Original Medicare beneficiaries can receive clinician-guided care and medical-grade connected tools to lower health risks at $0 out-of-pocket cost. September 15, 2026 10:00 ET | Source: AliveCor Inc. MOUNTAIN VIEW, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) - AliveCor, the global leader in AI-powered cardiology, today announced KardiaACCESS, a 10-year initiative under the Centers for Medicare & Medicaid Services (CMS) Innovation Center's ACCESS Model (Advancing Chronic Care with Effective, Scalable Solutions). Designed to go beyond passive monitoring, KardiaACCESS provides clinician-guided, outcome-aligned care to help people actively lower blood pressure, balance blood sugar, and manage their overall cardio-kidney-metabolic health. Managing chronic conditions often means brief doctor visits and trying to connect the dots alone. Regular monitoring is the key to identifying what is happening with your heart, and the KardiaACCESS program serves as the bridge to communicate with care teams both in and out of the doctor's office. KardiaACCESS treats connected health systems together - addressing the links between blood pressure, diabetes, lipids, and kidney function to deliver real health improvements and keep people out of the hospital. According to the American Heart Association, more than 70% of U.S. adults aged 60 to 79 live with cardiovascular disease. Furthermore, the Centers for Disease Control and Prevention (CDC) reports that three in four U.S. adults have at least one chronic condition, with interconnected issues like high blood pressure and diabetes serving as the primary drivers of chronic kidney and heart disease. "We've been helping patients manage heart health conditions for over a decade," said Priya Abani, CEO of AliveCor. "We know the center of chronic disease management often starts at the heart, and we are uniquely positioned to connect the dots across cardio-kidney-metabolic health. With KardiaACCESS, we provide active clinical guidance and medical-grade tools to help people manage their blood pressure, diabetes, lipids, and weight - empowering them to improve their real health numbers, reduce risks, and protect their hearts from home." Program Details: * 100% Covered ($0 Cost): Participating in the CMS ACCESS Model allows KardiaACCESS to offer complete program availability, dedicated clinical guidance, and health tools with $0 out-of-pocket cost. There are no co-pays, no deductibles, and no hidden fees for qualifying Original Medicare (Part B) beneficiaries. * Clinician-Guided Outcome Care: Expert guidance delivered by Kardia Medical Group, working alongside your routine care to provide active clinical guidance, progress checks, and doctor-ready reports. * Whole-Body Health Focus: Rather than treating symptoms in isolation, KardiaACCESS supports the complete Cardio-Kidney-Metabolic (CKM) system - helping lower systolic blood pressure, stabilize A1c, manage weight, and protect long-term kidney and heart function. * Connected Support & Tools: Program members receive connected devices, lifestyle coaching, virtual care visits, and Kardia app membership to keep their care team connected between routine doctor appointments. KardiaACCESS is currently available to eligible Original Medicare (Part B) beneficiaries in 48 states, with expansion to Arkansas and South Carolina coming soon. * Early Heart & Metabolic Support (eCKM Track): Diagnosed high blood pressure (hypertension) and/or high cholesterol, prediabetes, or overweight/obesity. * Established Condition Management (CKM Track): Diagnosed Type 2 diabetes, chronic kidney disease (CKD), or established heart disease/cardiovascular conditions. As the pioneer of personal, medical-grade electrocardiogram (ECG) technology, AliveCor brings unmatched clinical scale and validation to the ACCESS model. To date, the company's technology has supported more than 6.4 million patients globally and recorded over 400 million ECGs - a figure that continues to grow by more than one million recordings each week. Available in more than 40 countries, AliveCor's solutions are backed by more than 250 peer-reviewed publications and are cleared to detect 39 distinct cardiac conditions, including life-threatening heart attacks and ischemia. To learn more about KardiaACCESS and to check coverage and eligibility visit https://kardia.com/access. KardiaACCESS is provided by Kardia Medical Group, a clinical partner of AliveCor, in participation with the Centers for Medicare & Medicaid Services (CMS) ACCESS Model. KardiaACCESS is an outcome-aligned care program covered under Medicare Part B for eligible beneficiaries. Centers for Medicare & Medicaid Services (CMS) and KardiaACCESS are trademarks or registered trademarks. All care services and clinical evaluations are rendered under Cardiac Health Medical Group. About AliveCor AliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) devices, is transforming cardiology with its medical-grade AI solutions. The company was named to the inaugural TIME World's Top Health Tech Companies 2025 list - recognition of its commitment to delivering innovative devices and services that empower patients and physicians with personalized, actionable heart data. With over 400 million ECGs recorded, the company's Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company's latest offering, Kardia 12L ECG System, powered by KAI 12L cleared to detect 39 cardiac conditions (with determination availability varying by geography), was designed exclusively for use by healthcare providers. AliveCor's enterprise platform allows third-party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook. Media Contact Morgan Mathis Director of Corporate Communications, AliveCor [email protected]

AI cardiac diagnostics to skyrocket in 2036. Investing in healthcare's next frontier. Well, if you've been keeping an eye on where healthcare's dollars are heading, take note: AI-driven cardiac diagnostics is taking the lead, and it's set to make some noise in the investment circles. Investors Hangout, LLC is talking a jump from USD 903.2 million in 2026 to a staggering USD 2,805.1 million by 2036. That's a 12.0% CAGR, and it's not just smoke - it's the real deal driven by numbers and need. Why AI in cardiac diagnostics? Let's break it down. Investors Hangout, LLC is seeing hospitals and clinics going all-in on AI because heart disease isn't slowing down, folks. It's on a bull run, and traditional methods just aren't cutting the mustard anymore. Artificial intelligence offers a way to speed up the process - think faster ECG interpretations and smarter imaging analysis. The tech isn't just flashy; it improves outcomes and prioritizes cases that matter. Healthcare systems are feeling the pressure, big time. More heart patients, not enough specialists, and complex monitoring needs make AI an attractive proposition. It's not just about saving time; it's about saving lives. Key players and competitive edge. So, who's neck-deep in this AI revolution? Heavyweights like GE HealthCare, Philips, and upstarts like Eko Health and AliveCor are in the race. It's all about who delivers high-performance algorithms and can achieve clinical validation. Not an easy game, but one worth watching if you're the investing type. "Companies that combine validated algorithms with scalable deployment models will better position themselves for long-term growth." - Anurag Sharma, Principal Analyst at Future Market Insights Leading segments: who benefits most? * Technology: Machine learning is owning 30.5% of the market. It's the magic sauce that analyzes ECG data and improves prediction accuracy - a hot ticket in the cardiology world. * Applications: Arrhythmia Detection is leading the charge with 31.4% market share. Given the massive amount of ECG data from various sources - hospitals, outpatient centers, remote monitoring - AI tools for identifying irregularities are crucial. * End Users: Hospitals are not just observers in this space. They hold a solid 33.5% market share. Their resources make them prime adopters of AI platforms to boost workflow and sync departments like cardiology, radiology, and ER. Tech deployment: cloud dominates. Then there's the cloud, holding a whopping 64.0% of market designs from 2026. It's about scalability and ease of management. But don't get complacent; there's more complexity beneath the surface. Providers want it secure, seamless, and reliable - or they're not buying. Geographic growth: south Korea in the spotlight. Let's talk geography, folks. South Korea is striding ahead with a 13.4% CAGR. With connected hospital networks and a big push toward digital healthcare, this country is not just filling counts - it's filling bank accounts. The USA's advanced infrastructure helps it ride closely with a 12.8% growth rate. As for Europe? Germany and the UK are stepping up thanks to digital overhauls, and Japan faces its aging population dilemma with innovation. Future Market Insights: shaping strategy. Looking to strategize your next move? Future Market Insights isn't just about numbers. Their research turns market complexity into opportunities, allowing leadership teams to identify growth opportunities faster while reducing uncertainties. To summarize. If you're contemplating where health tech is heading in the next decade, pay attention. AI-driven cardiac diagnostics is set to double in size as the healthcare world demands more speed, efficiency, and data-driven insights. Be it cloud solutions or smarter algorithms, those ready to tackle this frontier will find a market ripe for investment and innovation.